LYEL Stock Overview
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Lyell Immunopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.27 |
| 52 Week High | US$8.74 |
| 52 Week Low | US$2.74 |
| Beta | 0 |
| 1 Month Change | -5.76% |
| 3 Month Change | -40.76% |
| 1 Year Change | -45.32% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.64% |
Recent News & Updates
Recent updates
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17Shareholder Returns
| LYEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.6% | 0.8% | 2.8% |
| 1Y | -45.3% | 7.1% | -9.2% |
Return vs Industry: LYEL underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: LYEL underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| LYEL volatility | |
|---|---|
| LYEL Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LYEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LYEL's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 219 | Lynn Seely | https://www.lyell.com |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications.
Lyell Immunopharma, Inc. Fundamentals Summary
| LYEL fundamental statistics | |
|---|---|
| Market Cap | US$815.29m |
| Earnings (TTM) | -US$258.43m |
| Revenue (TTM) | US$39.12m |
20.8x
P/S Ratio-3.2x
P/E RatioIs LYEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYEL income statement (TTM) | |
|---|---|
| Revenue | US$39.12m |
| Cost of Revenue | US$0 |
| Gross Profit | US$39.12m |
| Other Expenses | US$297.55m |
| Earnings | -US$258.43m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | 100.00% |
| Net Profit Margin | -660.62% |
| Debt/Equity Ratio | 0% |
How did LYEL perform over the long term?
See historical performance and comparison